June 28 - July 1 2017 Barcelona
![]() |
![]() |
![]() |
![]() |
1-LB | Efficacy, tolerability and impact on quality of life of ive internal radiation therapy (with yttrium 90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: the SARAH trial | Mohamed Bouattour | ![]() |
![]() |
|||
1-P | THE LONG-TERM RESULTS OF RADIOFREQUENCY ABLATION (RFA) IN PATIENTS WITH BARRETTS ESOPHAGUS RELATED NEOPLASIA | Jana Krajciova | ![]() |
![]() |
|||
1-PD | Interference of PG2 TATA BOX region with the serum PG2 level in Gastric Cancer | Renato Cannizzaro | ![]() |
![]() |
|||
2-LB | A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts) | Cindy Oh | ![]() |
![]() |
|||
3-LB | Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI /- Bevacizumab (bev) in metastatic colorectal cancer (mCRC) Patients (pts) | Marilyn Fontaine | ![]() |
![]() |
|||
5-PD | Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: results from a prospective screening study | Michael Davidson | ![]() |
![]() |
|||
5-P | Esophageal cancer patients survival after surgery significantly depended on cell ratio factors, blood cell circuit, biochemical factors, hemostasis system, adjuvant chemoimmunoradiotherapy, cancer characteristics, localization, anthropometric data | Oleg Kshivets | ![]() |
![]() |
|||
6-LB | Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving ive internal radiation therapy and chemotherapy as first-line therapy | Guy Van Hazel | ![]() |
![]() |
|||
6-P | Assessment of HER2 status in resected gastric cancer in european population | Nieves Martinez Lago | ![]() |
![]() |
|||
7-PD | Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3 | cecchi Fabiola | ![]() |
![]() |
|||
7-P | The metastatic lymph node ratio is an independent prognostic variable in hispanic patients with operable gastric cancer regardless of their TNM stage | Eugenia Cordero | ![]() |
![]() |
|||
9-PD | Overall survival in patients diagnosed with metastatic GEP-NET in Sweden | Daniel Granfeldt | ![]() |
![]() |
|||
9-O | Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment | Jordi Bruix | ![]() |
![]() |
|||
10-PD | A multi-cohort phase 1 study of ramucirumab plus durvalumab: preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma | Golan Talia | ![]() |
![]() |
|||
11-O | RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC) | Filippo Pietrantonio | ![]() |
![]() |
|||
11-P | The characteristics of HER2 and c-MET expression in gastric carcinoma and its correlation with clinical-pathological parameters. | Florian Dittmar | ![]() |
![]() |
|||
12-P | Loss of CDX2 is correlated to high grade and advanced stage in colorectal carcinoma Pathology Deapartement of FSI hospital TUNISIA | Haifa Rachdi | ![]() |
![]() |
|||
12-O | Impact of prior bevacizumab treatment on VEGFA and PlGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial. | Amber Wood | ![]() |
![]() |
|||
13-PD | Analysis of risk factors of early recurrence and ideal surgical margin for hepatocellular carcinoma | Hidetoshi NItta | ![]() |
![]() |
|||
13-P | Symptoms of Gastric Cancer From a Patient Perspective | Courtney Eavenson | ![]() |
![]() |
|||
14-O | PROGNOSTIC AND PREDICTIVE ROLE OF NEUTROPHILS/LYMPHOCYTES RATIO IN METASTATIC COLORECTAL CANCER: A RETROSPECTIVE ANALISYS OF THE TRIBE STUDY BY GONO. | Emanuela DellAquila | ![]() |
![]() |
|||
15-P | Epidemiology, treatment and prognostic factors of gastric adenocarcinoma in Tunisia | Nesrine Mejri | ![]() |
![]() |
|||
16-O | Associations of quality of life with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD | Larry Macke | ![]() |
![]() |
|||
16-PD | FIRST-LINE THERAPIES FOR ADVANCED PANCREATIC CANCER: A PERSPECTIVE BASED ON PHARMACOLOGICAL COSTS | Jacopo Giuliani | ![]() |
![]() |
|||
17-PD | CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy | Sam Wang | ![]() |
![]() |
|||
17-O | Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer | David Goldstein | ![]() |
![]() |
|||
18-PD | Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy | Floris de Jong | ![]() |
![]() |
|||
19-P | Gastric cancer in young patients: prognostics factors and therapeutic results | MARIAM BENHAMI | ![]() |
![]() |
|||
20-PD | Right- versus left-side metastatic colorectal cancer: differences in tumor biology and Bevacizumab efficacy. | Alessandro Passardi | ![]() |
![]() |
|||
20-O | Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma | Lipika Goyal | ![]() |
![]() |
|||
23-PD | Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated with Immunotherapy | Christine Parseghian | ![]() |
![]() |
|||
24-P | Metformin Inhibits Growth and Metastasis with Enhancement of Radiation Response in Hepatocellulcar Carcinoma Xenograft Model | Won Il Jang | ![]() |
![]() |
|||
24-PD | A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results(QUATTRO study) | Hideki Furuya | ![]() |
![]() |
|||
25-P | Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition | Sudhakar Chintharlapalli | ![]() |
![]() |
|||
25-PD | Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC):interim analysis from the prospective, observational CORRELATE study | Juan Manuel OConnor | ![]() |
![]() |
|||
26-P | Coffee and alcohol consumption and liver cancer morbidity rates in Poland | Miroslaw Jarosz | ![]() |
![]() |
|||
26-PD | Rechallenge with cetuximab irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximabirinotecan: the phase II CRICKET study by GONO. | Daniele Rossini | ![]() |
![]() |
|||
27-O | Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line ive internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer | farah dunlop | ![]() |
![]() |
|||
28-PD | Phase II Study of Tivantinib (ARQ 197) and Cetuximab in patients with EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) | Lorenza Rimassa | ![]() |
![]() |
|||
29-PD | Is Bevacizumab therapy safe in patients with Advanced Colorectal Cancer (CRC) and Self-Expandable Metal Stents(SEMS)? | Vilma Pacheco Barcia | ![]() |
![]() |
|||
29-P | Collaborative Storage and Research Use of Human Biospecimens between American University of Beirut and Memorial Sloan Kettering Cancer Center | WALID FARAJ | ![]() |
![]() |
|||
30-PD | Dose finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer: the initial safety analysis | Yosuke Kito | ![]() |
![]() |
|||
31-PD | Usefulness of 18F-FDG PET/CT, LDH and tumor markers in the prognosis and evaluation of tumor response after RMB therapy in advanced, metastatic colorectal cancer (mCRC) | Angelica Nazarian | ![]() |
![]() |
|||
32-PD | Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype | David Paez | ![]() |
![]() |
|||
32-P | Potential Protective Effects of Vitamin E in Cisplatin-induced Toxicity | Azadeh Moghaddas | ![]() |
![]() |
|||
34-P | Fat consumption and ed gastrointestinal cancers morbidity rates in Poland in the years 1960-2014 | Miroslaw Jarosz | ![]() |
![]() |
|||
38-P | The role of wnt/ -catenin associated with cell invasiveness in pancreatic cancer | Se Jun Park | ![]() |
![]() |
|||
40-P | Tanshinone IIA could decrease programmed death-ligand 1 expression in human pancreatic cancer cells in vitro | CHIN CHENG SU | ![]() |
![]() |
|||
44-P | Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: a single centre experience | Rob Owens | ![]() |
![]() |
|||
46-P | MORTALITY DURING DEFINITIVE CHEMORADIOTHERAPY IN OESOPHAGEAL CANCER | Danielle Shaw | ![]() |
![]() |
|||
53-P | Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease | Andrea Masarykova | ![]() |
![]() |
|||
59-P | Radical chemoradiotherapy for patients with locally advanced esophageal cancer. Long-term follow up of an ambispective study. | Milana Bergamino Sirvén | ![]() |
![]() |
|||
61-P | Role of palliative radiotherapy, chemotherapy and stents for dysphagia and quality of life improvement in advanced esophageal cancer. The optimal management? | Aseem Rai Bhatnagar | ![]() |
![]() |
|||
64-P | Lymphopenia Association with Planning Target Volume and Lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime | Tsz Him So | ![]() |
![]() |
|||
65-P | Application of gated FDG PET/CT in target volume definition for radiotherapy in esophageal cancer | Pierre Gustin | ![]() |
![]() |
|||
67-P | The effect of formalizing perioperative enhanced recovery protocol in esophageal surgery. | Maria Yan | ![]() |
![]() |
|||
68-P | Controversies in the treatment of esophageal squamous cell carcinoma: transthoracic or transhiatal approach | Maria Yan | ![]() |
![]() |
|||
71-P | Is Lymph Node Ratio in Surgical Treatment of Esophageal Squamous Cell Carcinoma Better than Classic TNM System? | Vítor Devezas | ![]() |
![]() |
|||
72-P | Pembrolizumab Versus Investigators Choice Single-AgentChemotherapy in Patients With Advanced/MetastaticEsophageal Adenocarcinoma That Progressed AfterFirst-Line Therapy: Phase 3 KEYNOTE-181 Study | Nonnon Kyle | ![]() |
![]() |
|||
76-P | Docetaxel in second line in advanced gastric cancer | REKAI kheira | ![]() |
![]() |
|||
77-P | Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting | William Schelman | ![]() |
![]() |
|||
78-P | A randomized trial of FOLFIRI versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancer | Sang Kil Lee | ![]() |
![]() |
|||
79-P | Discrepancy in Evaluating Her2 Overexpression in Signet Ring Gastric Cancer | Deborah Mukherji | ![]() |
![]() |
|||
80-P | Evaluation of morphology, HER2 status and its clinical and prognostic correlation in advanced gastric cancer: a prospective study at a tertiary referral center in Lebanon | Deborah Mukherji | ![]() |
![]() |
|||
81-P | Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States | Lisa Hess | ![]() |
![]() |
|||
82-P | PROGNOSTIC SIGNIFICANCE OF POSITIVE LYMPH NODE RATIO IN PATIENTS WITH pN3 GASTRIC CANCER WHO UNDERWENT CURATIVE GASTRECTOMY | Ahmet Bilici | ![]() |
![]() |
|||
84-P | The Detection of RNA for Carcinoembryonic Antigen and Cytokeratin 20 of Peritoneal Washing Fluids in Patients with Advanced Gastric Cancer | Se Eun Go | ![]() |
![]() |
|||
87-P | Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002) | RYOHEI KAWABATA | ![]() |
![]() |
|||
89-P | Efficacy and safety of modified Docetaxel, Cisplatine and 5FU (TPFm) in gastric cancer | Nesrine Mejri | ![]() |
![]() |
|||
90-P | Neoadjuvant chemotherapy in gastric cancer: evaluation of effectiveness | Mykola Zubaryev | ![]() |
![]() |
|||
96-P | The panitumumab with FOLFOX4 in metastatic Gastric or gastroesophageal Junction Adenocarcinoma (mGA) - VEGA trial. Efficacy and safety outcomes of a phase II S.I.C.O.G. study | VINCENZO FORMICA | ![]() |
![]() |
|||
97-P | The role of preoperative Computed Tomography for Node staging in Gastric Cancer: a centers retrospective analysis | Mário Fontes-Sousa | ![]() |
![]() |
|||
99-P | Clinicopathological characteristics in patients with bone Metastasis in GI Cancers | Yuki Shimizu | ![]() |
![]() |
|||
100-P | TREATMENT OF RECCURENT GASTRIC CANCER | Ivans Jelovskis | ![]() |
![]() |
|||
101-P | The validity and safety 1st-line Chemotherapy with Capecitabine/Oxaliplatin for Advanced Gastric Cancer | Yoshiaki Shindo | ![]() |
![]() |
|||
102-P | Intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: A single center retrospective analysis of 71 patients | Masahiro Yoshida | ![]() |
![]() |
|||
104-P | Real-world gastric cancer patients treated with at least three lines of chemotherapy: outcomes and predictors for efficacy. | Valentina Fanotto | ![]() |
![]() |
|||
105-P | Modified DOF regimen in advanced stomach cancer A single Centre experience from Bangalore. | SATHEESH THUNGAPPA | ![]() |
![]() |
|||
106-P | Prognostic factors in metastatic gastric cancer lets take a step forward | Amanda Nogueira | ![]() |
![]() |
|||
127-P | Evaluation of clinical benefit and safety of anastomotic perfusion measurement in reconstruction of gastrectomy using indocyanine green (ICG) enhanced fluorescence system | Mikito Mori | ![]() |
![]() |
|||
129-P | Multivisceral resections for T4 gastric cancer | Andrii Lukashenko | ![]() |
![]() |
|||
131-P | Impact of the number of lymph nodes harvested in gastric cancer patients prognosis | Hugo Santos Sousa | ![]() |
![]() |
|||
134-P | Safety and Efficacy of Low-dose Decitabine Primed Chemotherapy in Patients with Chemoresistant Relapsed/Refractory Gastrointestinal Cancers | Qian Mei | ![]() |
![]() |
|||
135-P | The role of serum tumour markers, inflammation-based markers and circulating tumour cells as surrogate biomarkers of early response to neoadjuvant systemic treatment in patients with resectable gastric cancer. | Katarzyna Marcisz-Grzanka | ![]() |
![]() |
|||
137-P | Analysis of surgical treatment for intrahepatic cholangiocarcinoma | Nanako Yasui | ![]() |
![]() |
|||
143-P | Prognostic Significance of VEGF and HIF 1 a in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin sorafenib combination | Shereen El Shorbagy | ![]() |
![]() |
|||
144-P | PECULIARITIES OF POSTOPERATIVE DYNAMICS OF BIOCHEMICAL INDICES OF THE LIVER FUNCTION DEPENDING ON THE CHARACTER OF FOCAL MASSES AND VOLUME OF LIVER RESECTION | Saidrakhim Lukmonov | ![]() |
![]() |
|||
145-P | Understanding the hepatocellular carcinoma (HCC) patient landscape: Results of the first global survey of people living with HCC | Jennifer Gill | ![]() |
![]() |
|||
147-P | High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer | Kyubo Kim | ![]() |
![]() |
|||
148-P | The Role of Quantitative TFPI2 Methylation as A Novel Serum Diagnostic and Prognostic Marker in Hepatopancreaticobiliary Cancers | Neslihan Erdem | ![]() |
![]() |
|||
149-P | C677T Single Nucleotide Polymorphism of Methylenetetrahydrofolate Reductase Gene and Colorectal Cancer | Alshimaa alhanafy | ![]() |
![]() |
|||
153-P | Management of anal cancer | REKAI kheira | ![]() |
![]() |
|||
154-P | Evaluation of risk factors predicting delayed chemotherapy-induced nausea and vomiting in patients receiving low emetic risk chemotherapy (LEC): A prospective, observational, multicenter study | Toshinobu Hayashi | ![]() |
![]() |
|||
156-P | Endoscopic and oncologic outcomes of gastroduodenal neuroendocrine tumors: A single center, large scale, retrospective study | Dong Seok Lee | ![]() |
![]() |
|||
157-P | THE PROGNOSTIC FACTORS FOR OPERATED GALLBLADDER CANCER | Ahmet Bilici | ![]() |
![]() |
|||
158-P | Prospective evaluation of PROMs and acute toxicity in VMAT planned radiotherapy for anal cancer and relation to planning constraints. | Camilla Kronborg | ![]() |
![]() |
|||
159-P | Epidemiologial study of 414 Gastrointestinal Stromal Tumors (GIST) Mexican patients. | German Calderillo | ![]() |
![]() |
|||
160-P | Prognosis factors of survival of Gallbladder cancer (GC) in Chile. A retrospective analysis of patients assisted in Hospital Clínico Universidad de Chile. | Silvia Catalán Elgueta | ![]() |
![]() |
|||
161-P | Can we still improve long term oncologic outcome of patients with anal carcinoma after multimodality treatment? | Rodica Anghel | ![]() |
![]() |
|||
164-P | FDG PET scanning suggests that 5FU myocardial toxicity is metabolic, rather than ischaemic | ANDREW DEAN | ![]() |
![]() |
|||
165-P | The Workload and Impact of a Dedicated Cancer of Unknown Primary (CUP) Service on Patients with Imaging Suggestive of Metastatic Disease. | Roopinder Gillmore | ![]() |
![]() |
|||
167-P | Efficacy and tolerance of XELOX plus Bevacizumab as first line therapy in Moroccan patients with metastatic colorectal cancer | Tarik Mahfoud | ![]() |
![]() |
|||
170-P | Managing patients with Carcinoma of Unknown Primary: a single UK centre experience | Rajarshi Roy | ![]() |
![]() |
|||
172-P | Temozolomide and Capecitabine in the treatment of Metastatic Digestive Neuroendocrine Tumor. The experience of a single Portuguese Cancer Centre. | Joana Carvalho | ![]() |
![]() |
|||
173-P | Bone metastasis from gastrointestinal cancer | Taik Mahfoud | ![]() |
![]() |
|||
178-P | Frequency Report of Irinotecan Toxicity in Iranian Population: Is genomic differences responsible? | Azadeh Moghaddas | ![]() |
![]() |
|||
179-P | Non size based morphology criteria for assessment of response in patients with liver metastases of GIT origin receiving systemic treatment | Alshimaa alhanafy | ![]() |
![]() |
|||
182-P | Stereotactic Body and Conformal Radiation Therapy in Primary and Secondary Liver Malignancies: Local in-field control. | Emily Latacz | ![]() |
![]() |
|||
183-P | An easy-to-handle DPD deficiency test in saliva to identify patients at high-risk for life-threatening toxicity due to fluoropyrimidine therapy. | andres Andrade Galarza | ![]() |
![]() |
|||
184-P | Gelatinous Peritoneal Disease (Service Experience). | Belkharoubi khedidja | ![]() |
![]() |
|||
185-P | Enhanced Recovery After Surgery (ERAS) program in patients undergoing major surgery for gastrointestinal cancer: Results of a 6-year clinical study. | Vasileios Alivizatos | ![]() |
![]() |
|||
186-P | Clinicopatological analysis of duodenal cancer undergone surgical resection | Masaru Inagaki | ![]() |
![]() |
|||
187-P | GIST- Retrospective analysis of a district hospital | Ins Guerreiro | ![]() |
![]() |
|||
188-P | The role of innovative surgical approaches in treatment of gastrointestinal stromal tumors | Mark Gluzman | ![]() |
![]() |
|||
191-P | Systemic Inflammation Response Index (SIRI): A Prognostic Factor in Pancreatic Cancer (PC) | Vilma Pacheco Barcia | ![]() |
![]() |
|||
194-P | Evaluation of CA 19-9, a predictive biomarker of response and survival in patients undergoing chemotherapy for metastatic pancreatic ductal adenocarcinoma | Doraid Alrifai | ![]() |
![]() |
|||
195-P | Second line treatment with 5-Fluorouracil and Folonic acid in Gemcitabine- pretreated advanced pancreatic cancer | REKAI kheira | ![]() |
![]() |
|||
199-P | Adjuvant therapy for pancreatic cancer: An updated analysis of treatment outcomes in elderly patients using the National Cancer Database (NCDB). | Donny Huynh | ![]() |
![]() |
|||
200-P | PANOVA-2: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma Updated efficacy results | Hugo Siedlecki | ![]() |
![]() |
|||
203-P | The relationship between metastatic status and Exosomal Marker (CD63) Expression Using Immunohistochemistry (IHC) in Patients with Pancreatic Ductal Adenocarcinoma (PDAC) | Brittany Case | ![]() |
![]() |
|||
206-P | Expanded analysis of mFOLFIRINOX as second-line chemotherapy in pancreatic adenocarcinoma | ANDREW DEAN | ![]() |
![]() |
|||
207-P | Chemoradiation in patients with locally advanced pancreatic adenocarcinoma | Oana Trifanescu | ![]() |
![]() |
|||
208-P | Resecting the unresectable - long course gemcitabine/nab-paclitaxel followed by chemoirradiation to downstage locally advanced pancreatic adenocarcinoma | Andrew Dean | ![]() |
![]() |
|||
210-P | The efficacy of single capecitabine as second-line treatment for gemcitabine refractory Pancreatic Cancer | Jae kyun Jeong | ![]() |
![]() |
|||
211-P | Venous thromboembolic event as prognostic marker in pancreatic and biliary tract cancer | Kabsoo Shin | ![]() |
![]() |
|||
212-P | Gemcitabine plus Capecitabine in elderly patients with advanced pancreatic cancer. | Vasiliki Michalaki | ![]() |
![]() |
|||
214-P | Outcomes of Older Versus Younger Patients With Metastatic Pancreatic Cancer: A Single Center Experience | Hseyin Engin | ![]() |
![]() |
|||
215-P | Progression-Free Survival is a Predictor of Survival in Patients with Untreated Metastatic Pancreatic Cancer: A Systematic Literature Review | Melanie Dearing | ![]() |
![]() |
|||
216-P | Treatment Patterns and Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Treated With First-Line nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records From the Flatiron Health Database | Elizabeth Dawn Flick | ![]() |
![]() |
|||
218-P | HCG Experience of Modified FOLFIRINOX regimen in advanced Pancreatic Cancer. | SATHEESH THUNGAPPA | ![]() |
![]() |
|||
219-P | Gemcitabine and Nab-Paclitaxel based regimen in advanced Pancreatic Carcinoma at tertiary cancer Centre, Bangalore | SATHEESH THUNGAPPA | ![]() |
![]() |
|||
220-P | Efficacy of oxaliplatin, irinotecan and erlotinib use regarding overall and progression-free survival in gemcitabine-based chemotherapy for locally advanced and metastatic pancreatic cancer. | Athanasios Tampakis | ![]() |
![]() |
|||
221-P | A simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer | Hugo Siedlecki | ![]() |
![]() |
|||
225-P | Two hundred Pancreaticoduodenectomies with No Intensive Care Unit Admission at a Single Center in the Middle East: Case for Sub-specialization | WALID FARAJ | ![]() |
![]() |
|||
226-P | Pancreaticoduodenectomy in the Middle East: A Single Center Experience | WALID FARAJ | ![]() |
![]() |
|||
228-P | Surgical treatment of pancreatic tumors in children | Andrii Lukashenko | ![]() |
![]() |
|||
229-P | PanCO: design of an open label, single arm pilot study of OncoSil in subjects with unresectable locally advanced pancreatic adenocarcinoma, given in combination with standard chemotherapy | Tom Maher | ![]() |
![]() |
|||
230-P | PANOVA-3: A phase 3 study of TTFields with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC) | Hugo Siedlecki | ![]() |
![]() |
|||
231-P | A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer | Vincent Picozzi | ![]() |
![]() |
|||
233-P | SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer | Somnath Mukherjee | ![]() |
![]() |
|||
234-P | Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients | Mehrdad Payandeh | ![]() |
![]() |
|||
236-P | Proteinase Levels in Colorectal Cancer Pathology and 15 Year Survival | LIZ BAKER | ![]() |
![]() |
|||
237-P | THE ASSOCIATION OF THE LEVEL SERUM OF INTERLEUKIN-10 AND ITS POLYMORPHISM GENE WITH THE RISK AND THE PROGNOSIS FOR COLORECTAL CANCER IN TUNISIA. | jihene ayari | ![]() |
![]() |
|||
239-P | Prognostic role of TRAP1 protein network in human metastatic colorectal carcinoma | Matteo Landriscina | ![]() |
![]() |
|||
240-P | suPAR as an additional prognostic factor in colorectal cancer | Ewa Wojcik | ![]() |
![]() |
|||
242-P | Correlation between clinical profile and molecular biology in patients from Eastern Algeria with colorectal cancer | athamnia houda | ![]() |
![]() |
|||
243-P | EMILIN2, extracellular matrix protein, as a regulator of the myeloid response in a model of inflammation-induced colon carcinogenesis. | Renato Cannizzaro | ![]() |
![]() |
|||
245-P | The survival and KRAS/BRAF testing in colorectal cancer: a review on the literature of Iran | Mehrdad Payandeh | ![]() |
![]() |
|||
249-P | Outcome analysis of synchronous liver limited vs synchronous lung limited resected metastases from colorectal cancer: a multicenter study | Haifa Rachdi | ![]() |
![]() |
|||
250-P | Neutrophil extracellular traps promote surgery-induced peritoneal carcinosis of metastatic colorectal cancer via modulation of CXCR2 and av integrin | Amr Al-Haidari | ![]() |
![]() |
|||
255-P | Autophagy (A) inhibition enhances combined immunotherapy (I) and anti EGFR treatment (E) in colorectal cancer (CRC) | Michalis Karamouzis | ![]() |
![]() |
|||
256-P | Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade | Sarah Novack | ![]() |
![]() |
|||
258-P | Factors influencing colorectal cancer screening participation rates in 2016 | Isabelle Lawrence | ![]() |
![]() |
|||
259-P | EVALUATION OF BRACHYSTEGIA EURYCOMA (HARMS) SEED DIETARY INCLUSION IN THE PREVENTION OF COLON CARCINOGENESIS | Sunday Atawodi | ![]() |
![]() |
|||
260-P | CHEMOPREVENTIVE EFFECT OF DIETARY PIPER NIGRUM SEED INCLUSION ON N-METHYL-N-NITROSOUREA-INDUCED COLON CARCINOGENESIS IN MALE ALBINO WISTAR RATS | Sunday Atawodi | ![]() |
![]() |
|||
261-P | EVALUATION OF THE PREVENTIVE EFFECTS OF TELFAIRIA OCCIDENTALLIS LEAF - SUPPLEMENTED DIET ON N-METHYL-N-NITROSOUREA (NMU) INDUCED COLON CARCINOGENESIS IN MALE WISTAR RATS | Sunday Atawodi | ![]() |
![]() |
|||
266-P | A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer | Takeshi Kajiwara | ![]() |
![]() |
|||
267-P | Colon cancer: pharmacogenetic approach to personalized conservative treatment | Jamshid Ibragimov | ![]() |
![]() |
|||
268-P | Lymphocyte-to-monocyte ratio in colorectal cancer patients | Zofia Stasik | ![]() |
![]() |
|||
269-P | Correlation between the prognostic value of tumor-infiltrating lymphocytes (TILS) and sidedness in colorectal cancer (CC) patients (pts) | cristina granetto | ![]() |
![]() |
|||
270-P | Prognostic value of molecular biomarkers in mCRC | Gonzalo García González | ![]() |
![]() |
|||
271-P | Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. | Roberto Moretto | ![]() |
![]() |
|||
272-P | Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT | Fabiola CECCHI | ![]() |
![]() |
|||
273-P | Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy. | Gemma Bruera | ![]() |
![]() |
|||
275-P | The choice of Irinotecan or Oxaliplatin-based chemotherapy in metastatic colo-rectal cancer as first line treatment: impact on survival (ERCC1 and TOPO1 adjusted analysis) | Eugeniu Banu | ![]() |
![]() |
|||
277-P | C-Kit and MSI in stage II Colorectal cancer; incidence and prognosis in Egyptian patients. | Mohamed Maher | ![]() |
![]() |
|||
278-P | Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment | Edita Baltruskeviciene | ![]() |
![]() |
|||
280-P | The molecular profile of colon cancer cells | Panagiotis Parsonidis | ![]() |
![]() |
|||
281-P | Expression of folate pathway genes with putative impact on leucovorin metabolism and outcome of patients with advanced colorectal cancer | Yvonne Wettergren | ![]() |
![]() |
|||
282-P | Pre-treatment Endogenous Interleukin-1 Receptor Antagonist (IL-1Ra) Levels in Metastatic Colorectal Cancer (mCRC) Patients are Associated with Clinical Outcomes After Anti-Interleukin-1a Therapy (MABp1) | Ashley Otero | ![]() |
![]() |
|||
284-P | Comparison of different sequences of combination chemotherapy and bevacizumab in patients with mKRAS colorectal cancer who received 2 lines of therapy: results of population register of 14 regions of Russia | Mikhail Fedyanin | ![]() |
![]() |
|||
285-P | Eliminating Fluorouracil Toxicity Without Sacrificing Efficacy In Colorectal Cancer | ECE ESIN | ![]() |
![]() |
|||
286-P | Evaluation of the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX regimen: a pooled analysis | Mototsugu Shimokawa | ![]() |
![]() |
|||
287-P | Body mass index and long-term outcomes in stage III colon cancer patients administered postoperative chemotherapy | JOLANTA ZOK | ![]() |
![]() |
|||
288-P | Prognostic but not predictive: focus on stage II right-sided colorectal cancer tumors | Andrea Palloni | ![]() |
![]() |
|||
289-P | Association of poor differentiation or positive vertical margin with residual disease in patients with subsequent colectomy after complete macroscopic endoscopic resection of early colorectal cancer | Hyun Seok Lee | ![]() |
![]() |
|||
293-P | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gastrointestinal cancers receiving moderately emetogenic chemotherapy regimens | Kelly Ostrander | ![]() |
![]() |
|||
295-P | Subgroup analysis by progression-free survival (PFS) of Asian patientstreated with regorafenib in the phase 3 CONCUR trial | Joachim Kalmus | ![]() |
![]() |
|||
296-P | Younger age at presentation of colorectal cancer; just a trend or different biology? | Salem Salem | ![]() |
![]() |
|||
297-P | Efficacy and toxicity results of FOLFIRI-Aflibercept in advanced colorectal cancer (CRCm) in real life, retrospective study. Prognostic factors and specific populations. | López López Carlos | ![]() |
![]() |
|||
298-P | Impact of Oxaliplatin on relapse in stage II and III colorectal cancer after primary therapy in Tunisian population | Nesrine Mejri | ![]() |
![]() |
|||
299-P | Prognostic value of tumor size in stage II and III colorectal cancer in Tunisian population | Nesrine Mejri | ![]() |
![]() |
|||
301-P | Bevacizumab in the first-line treatment of metastatic right-sided colon cancer: does it influence patients outcome? | Veronica Mollica | ![]() |
![]() |
|||
302-P | The best overall response to the first-line but not to the second-line treatment correlates with outcome of metastatic right-sided and left-sided colon cancer | Giorgio Frega | ![]() |
![]() |
|||
304-P | Incidence of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer treated by FOLFOX regimen at a regional community hospital in Québec. | jose luiz guimaraes | ![]() |
![]() |
|||
306-P | LLIVE: A Non-interventional Multicenter Study of First-line Avastin (Bevacizumab) in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon | Ali Shamseddine | ![]() |
![]() |
|||
307-P | Prognostic factors of Survival Outcomes in Colorectal Cancer Patients with Liver Metastasis | Pimtip Sanvarinda | ![]() |
![]() |
|||
310-P | Primary tumor site (pTS) as a key factor in influencing differential outcome in resected colorectal cancer patients treated with adjuvant XELOX/FOLFOX6 | Riccardo Giampieri | ![]() |
![]() |
|||
311-P | Regorafenib as third-line treatment for refractory metastatic Colorectal Cancer (mCRC): experience of Hospital de Navarra clinical practice. | Elena Mata Velasco | ![]() |
![]() |
|||
312-P | Clinical significance of peritoneal CEA detected during operation in patients with colorectal cancer | Jae Hyun Kim | ![]() |
![]() |
|||
313-P | First report : A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer : HGCSG1503 | Satoshi Yuki | ![]() |
![]() |
|||
314-P | Randomized Phase II Study of Cetuximab vs. Irinotecan and Cetuximab in Patients with Chemo-refractory KRAS codon G13D Metastatic Colorectal Cancer (G13D-study): Compared with ICECREAM study | Keiichiro Ishibashi | ![]() |
![]() |
|||
315-P | A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal CancerHGCSG1401 : Analysis of tumor location | Satoshi Yuki | ![]() |
![]() |
|||
316-P | Prognostic Role of RDW-Platelet Ratio (RPR) in Advanced Colorectal Cancer | Hseyin Engin | ![]() |
![]() |
|||
317-P | Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cáncer: Safety and efficacy in a real-life population. | Beatriz González | ![]() |
![]() |
|||
318-P | Properties of the Iranian version of colorectal cancer specific quality of life questionnaire (EORTC QLQ-CR29) | Sanambar Sadighi | ![]() |
![]() |
|||
319-P | Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer | Dawn Batty | ![]() |
![]() |
|||
320-P | Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes | Batty Dawn | ![]() |
![]() |
|||
321-P | Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment | Marc Peeters | ![]() |
![]() |
|||
322-P | TUMOR LOCATION IN PATIENTS WITH COLORECTAL CANCER TREATED WITH BEVACIZUMAB. | Beatriz González | ![]() |
![]() |
|||
324-P | MITOMYCIN-C (MTC) AS SALVAGE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC) | Jelena Spasic | ![]() |
![]() |
|||
325-P | The impact of primary tumor site and anti-VEGF therapy in metastatic colorectal cancer | Ana Pissarra | ![]() |
![]() |
|||
326-P | Size does matter: comparison of activity between anti-EGFR and anti-VEGF based-treatments in RAS wild type colorectal cancer patients, stratified by sizes of metastatic involvement | Michela Del Prete | ![]() |
![]() |
|||
328-P | Sidedness and TP53 Mutations Impact OS in anti-EGFR But Not anti-VEGF treated mCRC - An Analysis of the KRAS Registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) | Florian Huemer | ![]() |
![]() |
|||
329-P | Stereotactic body radiotherapy: a promising approach for colorectal lung oligometastases. | Kevin Molina Mata | ![]() |
![]() |
|||
330-P | Retreatment with FOLFOX for patients with metastatic colorectal cancer- single center experience | Marija Ristic | ![]() |
![]() |
|||
331-P | Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals | Beatriz González | ![]() |
![]() |
|||
335-P | Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population. | Gonalo Atalaia | ![]() |
![]() |
|||
338-P | RELATIONSHIP BETWEEN PRIMARY TUMOR LOCATION AND ONCOGENES MUTATIONS IN METASTATIC COLORECTAL CANCER. | Braulio Martin Calero | ![]() |
![]() |
|||
340-P | Increase in Spleen Volume as a Predictor of Oxaliplatin toxicity | Ali Shamseddine | ![]() |
![]() |
|||
344-P | Clinical Predictive Factors for Surgery in Stage IV MCRC (wt) | María Geist | ![]() |
![]() |
|||
345-P | Surgical resection of primary tumors in patients with stage IV colorectal cancer and unresectable liver metastases | LOURDES CALERA URQUIZU | ![]() |
![]() |
|||
347-P | Single-incision versus conventional laparoscopic approach in colorectal cancer surgery | LIZ BAKER | ![]() |
![]() |
|||
351-P | Simultaneous and staged resections in patients with synchronous colorectal liver metastases | Mykola Zubaryev | ![]() |
![]() |
|||
353-P | Design of a phase II study evaluating trifluridine/tipiracilbevacizumab and capecitabinebevacizumab for first-line treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy (TASCO1) | Sarah Novack | ![]() |
![]() |
|||
355-P | The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb) | Sarah Novack | ![]() |
![]() |
|||
359-P | BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer | Sarah Pearce | ![]() |
![]() |
|||
360-P | Radical multimodality treatment for locally-recurrent rectal cancer outcomes and potential prognostic factors | Thomas Bird | ![]() |
![]() |
|||
362-P | Neoadjuvant chemotherapy prior to chemoradiation and surgery for rectal cancer: tolerability, pathological and survival outcomes for a high risk cohort | Gary Doherty | ![]() |
![]() |
|||
363-P | Longer Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: a monocentric experience. | roberto murialdo | ![]() |
![]() |
|||
366-P | Prognostic markers of tumour recurrence and survival of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and radical surgery: a retrospective study. | Michael Abdalmassih | ![]() |
![]() |
|||
367-P | A phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer | Brigette Ma | ![]() |
![]() |
|||
369-P | Treatment in locally advance rectal cancer: Single-center experience. | Mariana Rocha | ![]() |
![]() |
|||
372-P | Dose escalation utilising a simultaneous integrated boost (SIB) in rectal cancer: outcome of acute toxicity and response | Rob Owens | ![]() |
![]() |
|||
374-P | Treatment of synchronous rectal and prostate cancer utilising intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB): assessment of acute toxicity and response. | Rob Owens | ![]() |
![]() |
|||
378-P | Impact of diverting stoma in low anterior resection for rectal cancer on short-term surgical outcomes and reoperation | Hussein Fakhry | ![]() |
![]() |
June 28 - July 1 2017 Barcelona
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|